A 68-year-old man with chronic renal failure developed hyperkalemia during continuous hemodiafiltration (CHDF) most likely due to nafamostat mesirate (NM) administration. He went into cardiopulmonary arrest due to pulmonary edema. Immediately, he was treated by CHDF with NM 30mg•hr
-1 under mechanical ventilation. His serum K
+ level was 4.7mEq•l
-1 on admission, and it rose gradually until it reached a maximum of 6.5mEq•l
-1, 25 hours later. Neither hyperventilation, bicarbonate i.v. nor glucose-insulin therapy were successful in reducing the serum K
+ level. NM was replaced by heparin. Thereafter the serum K
+ level decreased and normalized.Hyperkalemia is one of the side effects of NM. The mechanism of NM-induced
hyperkalemia has been attributed to the suppression of the potassium excretion mechanism in renal tubules. However, this was not likely with our case, because he had been anuric due to chronic renal failure. We assumed that extrarenal NM effects caused this hyperkalemia.
View full abstract